Table 1 Baseline demographics of the treatment group

Gender (n = 170)

Female

74 (44%)

Male

96 (56%)

65.5 [56.0–73.0]

Race (n = 170)

American Indian or Alaska Native

0 (0%)

Asian

3 (2%)

Black or African American

16 (9%)

Native Hawaiian or Pacific Islander

1 (1%)

White or Caucasian

140 (82%)

Unknown

7 (4%)

Other

3 (2%)

Ethnicity (n = 170)

Hispanic or Latino

19 (11%)

Non-Hispanic

137 (81%)

Unknown

14 (8%)

Other

0 (0%)

Enrollment Year (n = 170)

2015

7 (4%)

2016

37 (22%)

2017

68 (40%)

2018

26 (15%)

2019

23 (14%)

2020

9 (5%)

ECOG (n = 164)

0

78 (48%)

1

61 (37%)

2 or more

25 (15%)

Grade (n = 81)

Well Differentiated

57 (70%)

Moderately Differentiated

12 (15%)

Poorly Differentiated

12 (15%)

Tumor Site (n = 152)

Foregut

39 (26%)

Midgut

54 (36%)

Pancreas

36 (24%)

Hindgut

10 (7%)

Unknown

13 (9%)

25.9 [11.9–49.8]

Tumor Location (n = 165)

Bilobar

77 (47%)

Unilobar

88 (53%)

Yes (n = 77, 48%)

Lung

22 (29%)

Lymph Nodes

22 (29%)

Bone

14 (18%)

Peritoneum

9 (12%)

Small Bowel

6 (8%)

Brain

1 (1%)

Gastric

1 (1%)

Large Bowel

1 (1%)

Prostate

1 (1%)

Uterus

1 (1%)

Other

28 (36%)

Hepatic Resection

Yes

23 (14%)

Systemic Therapy (n = 144)

Octreotide

119 (83%)

Biologic

49 (34%)

Cytotoxic

58 (40%)

Arterial Embolization (n = 166)

Yes

62 (37%)

No

104 (63%)

Biliary Intervention (n = 15)

Metallic Stent

2 (13%)

Plastic Stent

1 (7%)

Percutaneous Biliary Drainage

1 (7%)

Surgical Anastomosis

5 (31%)

Other

7 (47%)

10 (6%)

Baseline Laboratories

Bilirubin in mg/dL (Median [IQR])

0.9 [0.6–1.4]

Albumin in g/dL (Median [IQR])

4.1 [3.8–4.3]

ALT in u/L (Median [IQR])

42.0 [23.8–73.0]

AST in u/L (Median [IQR])

52.0 [28.0–72.0]

INR Ratio (Median [IQR])

1.1 [1.0–1.3]

Creatinine in mg/dL (Median [IQR])

1.1 [0.9–1.4]

Chromogranin A in ng/mL (Median [IQR])

543 [215–2981]

Platelet Count in thousands/uL (Median [IQR])

239.5 [170.5–315.8]